* New data analyses from phase 3 attain trials support
Vibativ(telavancin) as a treatment for staphylococcus aureus
HABP/VABP, including cases caused by MRSA
Source text for Eikon:
Further company…
The post BRIEF-Theravance says new data analyses from phase 3 attain trials support vibativ as a treatment for staphylococcus aureus HABP/VABP appeared first on NASDAQ.